

Estimated Glomerular Filtration Rate, Albuminuria, and Adverse Outcomes An Individual-Participant Data Meta-Analysis

Writing Group for the CKD Prognosis Consortium

 [Supplemental content](#)

IMPORTANCE Chronic kidney disease (low estimated glomerular filtration rate [eGFR] or albuminuria) affects approximately 14% of adults in the US.

OBJECTIVE To evaluate associations of lower eGFR based on creatinine alone, lower eGFR based on creatinine combined with cystatin C, and more severe albuminuria with adverse kidney outcomes, cardiovascular outcomes, and other health outcomes.

DESIGN, SETTING, AND PARTICIPANTS Individual-participant data meta-analysis of 27 503 140 individuals from 114 global cohorts (eGFR based on creatinine alone) and 720 736 individuals from 20 cohorts (eGFR based on creatinine and cystatin C) and 9 067 753 individuals from 114 cohorts (albuminuria) from 1980 to 2021.

EXPOSURES The Chronic Kidney Disease Epidemiology Collaboration 2021 equations for eGFR based on creatinine alone and eGFR based on creatinine and cystatin C; and albuminuria estimated as urine albumin to creatinine ratio (UACR).

MAIN OUTCOMES AND MEASURES The risk of kidney failure requiring replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, any hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. The analyses were performed within each cohort and summarized with random-effects meta-analyses.

RESULTS Within the population using eGFR based on creatinine alone (mean age, 54 years [SD, 17 years]; 51% were women; mean follow-up time, 4.8 years [SD, 3.3 years]), the mean eGFR was 90 mL/min/1.73 m² (SD, 22 mL/min/1.73 m²) and the median UACR was 11 mg/g (IQR, 8-16 mg/g). Within the population using eGFR based on creatinine and cystatin C (mean age, 59 years [SD, 12 years]; 53% were women; mean follow-up time, 10.8 years [SD, 4.1 years]), the mean eGFR was 88 mL/min/1.73 m² (SD, 22 mL/min/1.73 m²) and the median UACR was 9 mg/g (IQR, 6-18 mg/g). Lower eGFR (whether based on creatinine alone or based on creatinine and cystatin C) and higher UACR were each significantly associated with higher risk for each of the 10 adverse outcomes, including those in the mildest categories of chronic kidney disease. For example, among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m² based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m² (adjusted hazard ratio, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]).

CONCLUSIONS AND RELEVANCE In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations.

JAMA. 2023;330(13):1266-1277. doi:10.1001/jama.2023.17002

Group Information: The members of the Writing Group for the CKD Prognosis Consortium appear at the end of the article. The members of the CKD Prognosis Consortium are listed in Supplement 3.

Corresponding Author: Morgan E. Grams, MD, PhD, 227 E 30th St, Unit 825, New York, NY 10016 (ckdpc@jhmi.edu).

Chronic kidney disease (CKD), which is defined by albuminuria (urine albumin to creatinine ratio [UACR] ≥ 30 mg/g/d) or a glomerular filtration rate (GFR) less than 60 mL/min/1.73 m² that persists for at least 3 months, affects approximately 14% of adults in the US.¹ Both lower estimated GFR (eGFR) values and more severe albuminuria have been associated with higher rates of kidney failure with replacement therapy, acute kidney injury, all-cause mortality, and cardiovascular mortality.²⁻⁶

This study evaluated associations of albuminuria, eGFR, and the combination of albuminuria and eGFR with 10 adverse health outcomes, consisting of incident kidney failure with replacement therapy, all-cause mortality, cardiovascular mortality, acute kidney injury, hospitalization, coronary heart disease, stroke, heart failure, atrial fibrillation, and peripheral artery disease. Associations were evaluated within subgroups of age, sex, and presence of diabetes and cardiovascular disease. The eGFR was assessed using race-free equations that incorporated creatinine alone or both creatinine and cystatin C.⁷ The prespecified analyses included evaluating whether eGFR based on creatinine and cystatin C was more strongly associated with adverse outcomes compared with eGFR based on creatinine alone.

Methods

Study Population

Investigators in the CKD Prognosis Consortium (ckdpc.org) were invited to participate in the current meta-analysis if their represented cohorts included individuals with both eGFR and albuminuria as well as having 50 events or more for at least 1 of the selected outcomes. For measures of prevalence and absolute incidence of adverse outcomes, we used data from the Optum Labs Data Warehouse, which is a data set with deidentified administrative claims and electronic health records for patients who were followed up longitudinally. The data derived from the electronic health records included a subset that was normalized and standardized into a single database.⁸ The study was approved by the institutional review board (IRB) at the Bloomberg School of Public Health, Johns Hopkins University. The data were preexisting and deidentified; however, in accordance with individual cohort policies, the study underwent expedited IRB approval. The IRB waived the requirement for informed consent.

Kidney Measures

All individuals had serum creatinine measurements with eGFR based on creatinine alone estimated using the race-free Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) 2021 creatinine equation.⁷ A subset of the population had serum creatinine and cystatin C measurements with eGFR estimated using the CKD-EPI 2021 creatinine-cystatin C equation. The methods for the creatinine and cystatin C measurements for each cohort are described in eAppendix 1 in Supplement 1.⁹⁻¹¹ The categories of eGFR were 105 mL/min/1.73 m² or greater, 90 to 104 mL/min/1.73 m², 60 to 89 mL/min/1.73 m², 45 to 59 mL/min/1.73 m², 30 to

Key Points

Question Are lower values for estimated glomerular filtration rate (eGFR based on either creatinine alone or creatinine and cystatin C) and more severe albuminuria associated with adverse kidney and cardiovascular outcomes?

Findings In this retrospective individual-level data analysis of 27 503 140 individuals from 114 cohorts, lower eGFR and more severe albuminuria were each associated with higher rates of adverse kidney outcomes, including kidney failure with replacement therapy and acute kidney injury. Lower eGFR and more severe albuminuria also were associated with adverse cardiovascular outcomes, including cardiovascular mortality, heart failure, and atrial fibrillation.

Meaning Lower eGFR values and more severe albuminuria were associated with multiple adverse outcomes.

44 mL/min/1.73 m², 15 to 29 mL/min/1.73 m², and less than 15 mL/min/1.73 m².

Albuminuria was measured and calculated as UACR, urine protein to creatinine ratio, or dipstick proteinuria. For the former 2 methods, both spot and 24-hour collections were accepted. For the latter 2 methods, the values were extrapolated to the UACR using a previously published multivariable conversion equation.¹² In the categorical analyses, dipstick proteinuria categories of negative, trace, 1+, 2+, and 3+ or 4+ were classified into the UACR categories of less than 10 mg/g, 10 to 29 mg/g, 30 to 299 mg/g, 300 to 999 mg/g, and 1000 mg/g or greater, respectively. In the sensitivity analyses without dipstick values, all dipstick measures were classified in the missing UACR category.

Outcomes

The following outcomes were requested for each cohort: all-cause mortality, cardiovascular mortality (death due to cardiovascular disease), kidney failure with replacement therapy (receipt of chronic dialysis or kidney transplant), all-cause hospitalization, and hospitalizations for stroke (ischemic or hemorrhagic), myocardial infarction, heart failure (any hospitalization or death with heart failure), acute kidney injury, atrial fibrillation, and peripheral artery disease. Some of the cohorts were linked to the US Renal Data System¹³ to ascertain kidney failure with replacement therapy, some of the cohorts performed expert adjudication for specific outcomes, and some of the cohorts identified outcomes based on coding alone using the *International Classification of Diseases, Ninth Revision*, or the *International Statistical Classification of Diseases and Related Health Problems, Tenth Revision*. Cohort-specific outcome definitions appear in eAppendix 1 in Supplement 1. Individuals with a history of the outcome were excluded from the analyses of incident events. Each cohort contributed between 1 and 10 analyses, depending on the outcomes available for each cohort. General population cohorts with fewer than 50 events for a specific outcome and CKD cohorts with fewer than 25 events were excluded from the meta-analysis for the corresponding outcome.

Statistical Analyses

Cox proportional hazards models were used to relate kidney measurements to adverse outcomes separately in each cohort. Random-effects models were used for the meta-analysis of the hazard ratios (HRs). The kidney measurements were collected at a single visit. In the categorical analyses, individuals were classified by the categories of eGFR (<15, 15-29, 30-44, 45-59, 60-89, 90-104, and ≥ 105 mL/min/1.73 m²) and UACR (<10, 10-29, 30-299, 300-999, and ≥ 1000 mg/g). The models included interaction terms for all combinations of the eGFR and UACR categories (eg, the product terms of eGFR <15 mL/min/1.73 m² and UACR <10 mg/g; eGFR of 15-29 mL/min/1.73 m² and UACR <10 mg/g; and eGFR of 30-44 mL/min/1.73 m² and UACR <10 mg/g, etc). The reference group was set as an eGFR of 90 to 104 mL/min/1.73 m² and a UACR less than 10 mg/g. Because the CKD cohorts lacked individuals in the reference group, only general population and electronic health record cohorts were used in the categorical analyses.

Because fewer individuals had data to contribute to the eGFR analyses based on creatinine and cystatin C, the less common categories of eGFR and UACR were combined to ensure adequate numbers of events. Hence, the 2 lowest categories of eGFR were combined (<15 and 15-29 mL/min/1.73 m²) and the 2 highest categories of UACR were combined (300-999 and ≥ 1000 mg/g). Model adjustment differed depending on the outcome and included a subset of the following covariates: age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body mass index, use of antihypertensive medications, and a history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease when relevant (eg, an analysis of incident peripheral artery disease as an outcome would not include peripheral artery disease as an adjustment variable). All covariate definitions and models appear in eAppendix 1 in [Supplement 1](#).

Quantitative covariates were included in the model using a continuous scale. The missing data for albuminuria were treated as a separate category when the missingness exceeded 10% in a given cohort, otherwise a complete case analysis was performed. For other variables, the extent and handling of missing data are detailed in eTable 1 in [Supplement 2](#) and in eAppendix 1 in [Supplement 1](#). Models were run overall and by stratum for age (<65 years, ≥ 65 years) and sex (female, male).

To facilitate comparison of associations across cohorts, outcomes, and by filtration marker (eGFR based on creatinine alone vs eGFR based on creatinine and cystatin C), eGFR and UACR were also modeled continuously with linear spline terms and knots at eGFRs of 60 mL/min/1.73 m² and 105 mL/min/1.73 m² and log transformation for UACR. The model parameters were otherwise identical to those of the categorical analyses. Continuous analyses were performed in all cohorts, including the general population, electronic health record, and CKD cohorts. The meta-analysis of β coefficients from the Cox proportional hazards models used random effects as detailed above.

Forest plots were examined to assess the heterogeneity of the effect sizes across cohorts and cohort characteristics. Sub-

group analyses were performed by age, sex, diabetes, and presence of cardiovascular disease. In the sensitivity analyses, continuous associations also were examined using other estimating equations for GFR, including previous CKD-EPI equations^{14,15} (CKD-EPI 2009 equation for eGFR based on creatinine alone and CKD-EPI 2012 equation for eGFR based on creatinine and cystatin C), but only using the non-Black (NB) race value, and European Kidney Function Collaboration (EKFC) equations¹⁶ (EKFC equations for eGFR based on creatinine alone and for eGFR based on creatinine and cystatin C).

After the meta-analysis of the β coefficients (log HRs), we compared log HRs within each combined category of eGFR and UACR across populations or subgroups of populations using matched-pair Wilcoxon signed rank tests. The between-population differences were summarized using medians and IQRs. A *P* value <.05 was considered statistically different.

The largest cohort, the Optum Labs Data Warehouse (electronic health records for populations of patients in the US) was used to estimate the prevalence for the eGFR and UACR categories and the unadjusted incidence rates for each adverse outcome within the categories of eGFR and UACR. For these analyses, single measurements for eGFR and albuminuria were used. The incidence of adverse outcomes was estimated individually within each of the 39 health systems and summarized as a median cohort value across each health system (eg, 19 health systems had higher incidence rates and 19 health systems had lower incidence rates). Adjusted excess incidence (ie, the difference in incidence comparing 1 combined eGFR and UACR category vs the reference category) was estimated by treating incidence rates in the median health system in the reference group among the Optum Labs Data Warehouse cohorts as a constant and combining the HRs from the meta-analysis for each group in the categorical analysis of eGFR based on creatinine alone.

All analyses were conducted using Stata MP version 16.1 (StataCorp). All statistical testing was 2-sided. Statistical significance was determined by *P* < .05.

Results

Study Population

A total of 120 cohorts were evaluated. Of these 120 cohorts, the individual cohort principal investigators refused to provide data for 2 cohorts and were unable to send data or perform the analysis within the time allotted for 4 cohorts, leaving 114 cohorts in this individual-participant data meta-analysis. The data sources included 37 observational studies or clinical trials of individuals identified from the general population, 49 electronic health record databases, and 28 observational studies or clinical trials of adults with CKD. Additional information on the included cohorts appears in eAppendix 1 and eAppendix 2 in [Supplement 1](#).

Population With eGFR Based on Creatinine Alone

Of the 120 cohorts evaluated for inclusion, 114 cohorts including 27 503 140 individuals had data available for eGFR based on creatinine alone and were included in the

Table 1. Participant Characteristics for the Estimated Glomerular Filtration Rate (eGFR) Based on Creatinine Alone or Creatinine and Cystatin C

	eGFR based on creatinine alone	eGFR based on creatinine and cystatin C
No. of cohorts	114	20
No. of individuals ^a	27 503 140	721 394
Age, mean (SD), y	54 (17)	59 (12)
Sex, %		
Female	51	53
Male	49	47
Follow-up, mean (SD), y	4.8 (3.3)	10.8 (4.1)
Comorbid conditions, %		
Taking medications for hypertension	16.6	27.0
Diabetes	15.2	9.4
Former smoking	13.1	35.0
Current smoking	10.6	11.5
Coronary heart disease	9.9	6.3
History of cancer	13.0	10.8
Chronic obstructive pulmonary disease	7.5	2.4
Atrial fibrillation	4.5	4.7
History of heart failure	3.5	3.2
History of stroke	3.2	3.5
Peripheral artery disease	1.6	1.0
Vital signs and laboratory studies		
Systolic blood pressure, mean (SD), mm Hg	126 (17)	138 (20)
Body mass index, mean (SD) ^b	29 (7)	28 (5)
Cholesterol, mean (SD), mmol/L		
Total	4.7 (1.3)	5.0 (1.1)
High-density lipoprotein	1.3 (0.4)	1.3 (0.4)
eGFR, mean (SD), mL/min/1.73 m ²		
Based on creatinine alone	90 (22)	89 (20) ^c
Based on creatinine and cystatin C		88 (22)
Urine albumin to creatinine ratio, median (IQR), mg/g ^d	11 (8-16)	9 (6-18)

SI conversion factors: To convert high-density and total cholesterol to mg/dL, divide by 0.0259.

^a Not necessarily the denominator for each characteristic. The proportion with missing data for each characteristic appears in eTable 1 in Supplement 2. Detailed definitions of each of these characteristics appear in eAppendix 1 in Supplement 1.

^b Calculated as weight in kilograms divided by height in meters squared.

^c Based on creatinine alone.

^d These data for measurement of albuminuria represent less than 50% of the analytic population (9 067 753 [33.0%] for eGFR based on creatinine alone and 320 443 [44.4%] for eGFR based on creatinine and cystatin C).

analyses (Table 1). Among these individuals, the mean age was 54 years (SD, 17 years), 51% were women, the mean eGFR based on creatinine alone was 90 mL/min/1.73 m² (SD, 22 mL/min/1.73 m²), and 33.0% had measures of albuminuria. Of those with albuminuria measures, the median UACR was 11 mg/g (IQR, 8-16 mg/g). The number of cohorts contributing to each outcome ranged from 52 (for acute kidney injury) to 108 (for all-cause mortality). The rates of adverse outcomes were lowest for peripheral artery disease (median rate among 62 cohorts, 1.4 events per 1000 person-years) and kidney failure with replacement therapy (median rate among 83 cohorts, 1.3 events per 1000 person-years) and highest for hospitalizations (median rate among 52 cohorts, 94 events per 1000 person-years) (eTable 2 in Supplement 2).

Population With eGFR Based on Creatinine and Cystatin C

There were 20 cohorts included with 721 394 individuals that had data for cystatin C (eGFR based on creatinine and cystatin C population). Among these individuals, the mean age was 59 years (SD, 12 years), 53% were women, the mean eGFR

was 89 mL/min/1.73 m² (SD, 20 mL/min/1.73 m²) based on creatinine alone vs 88 mL/min/1.73 m² (SD, 22 mL/min/1.73 m²) based on creatinine and cystatin C, and 44.4% had measures of albuminuria. Of those with albuminuria measures, the median UACR was 9 mg/g (IQR, 6-18 mg/g).

Both Populations

The clinical characteristics for each cohort appear in eTable 3 in Supplement 2 (eGFR based on creatinine alone population) and in eTable 4 in Supplement 2 (eGFR based on creatinine and cystatin C population). Most individuals who were missing albuminuria data came from the electronic health record cohorts (95.4% of the population for eGFR based on creatinine alone and 99.8% of the population for eGFR based on creatinine and cystatin C). For the analyses of eGFR based on creatinine alone, the mean follow-up time was 4.8 years (SD, 3.3 years). For the analyses of eGFR based on creatinine and cystatin C, the mean follow-up was 10.8 years (SD, 4.1 years) and the number of cohorts contributing data ranged from 3 (for hospitalizations) to 20 (for all-cause mortality) (eTable 5 in Supplement 2).

Analyses According to eGFR Based on Creatinine Alone and UACR

In the categorical analyses of eGFR based on creatinine alone, compared with the reference category of 90 to 104 mL/min/1.73 m², the lower categories (eGFR ≤60 mL/min/1.73 m²) were significantly associated with higher risk for each outcome. Compared with the reference UACR category of less than 10 mg/g, the higher categories were associated with higher rates for each outcome (Figure 1). Risks among people with missing UACR data were comparable with those within the UACR category of 10 to 29 mg/g (median difference in log HRs, −0.03 [IQR, −0.11 to 0.09], *P* = .39; eTable 6 in Supplement 2). The patterns of risk associations were similar across each age category and among men and women, although the relative risks (RRs) were weaker in the older age (≥65 years) category compared with the younger age (<65 years) category (median difference in log HRs, −0.45 [interquartile interval {IQI}, −0.70 to −0.14], *P* < .001) and very slightly stronger in women compared with men (median difference in log HRs, 0.04 [IQI, −0.05 to 0.13], *P* < .001; eTable 7 in Supplement 2).

Compared with an eGFR of 90 to 104 mL/min/1.73 m² based on creatinine alone, the CKD category of G3a (an eGFR of 45–59 mL/min/1.73 m² based on creatinine alone) was significantly associated with higher adjusted HRs for each outcome, even among people with a UACR less than 10 mg/g, a UACR of 10 mg/g to less than 30 mg/g, or in those with missing UACR (Table 2). When stratified by age and sex, the RRs for the CKD category of G3a were smaller among older adults (≥65 years of age) compared with younger adults (<65 years of age) (median difference in log HRs, −0.36 [IQI, −0.49 to −0.27], *P* < .001); however, all remained statistically significant except for hospitalizations among older adults with missing data for UACR. The RR comparisons between men and women were not significantly different (median difference in log HRs, 0.02 [IQI, −0.04 to 0.07], *P* = .19; eTable 8 in Supplement 2).

In the continuous analyses, the HRs for the spline term for lower eGFR (<60 mL/min/1.73 m²) and an 8-fold higher UACR were highest for kidney failure with replacement therapy (HR for eGFR <60 per 15 mL/min/1.73 m², 3.89 [95% CI, 3.73–4.06]), and all (for eGFR) or nearly all (for UACR) associations were statistically significant in the individual cohorts (eTable 9 in Supplement 2 and the eFigure in Supplement 1). In the sensitivity analyses excluding albuminuria measured by dipstick, the UACR associations were not statistically different from those when the dipstick measures were included (median difference in log HRs, −0.02 [IQI, −0.02 to −0.004], *P* = .06; eTable 10 in Supplement 2). The HRs by subgroup of age, sex, diabetes, and cardiovascular disease appear in eTable 11 in Supplement 2.

Analyses According to eGFR Based on Creatinine and Cystatin C and UACR

In the categorical analyses of eGFR based on creatinine and cystatin C, compared with the reference category of 90 to 104 mL/min/1.73 m², the eGFR categories below 60 mL/min/1.73 m² were significantly associated with higher risk for

each outcome. Compared with the UACR reference category of less than 10 mg/g, higher UACR categories were associated with higher rates for each outcome (Figure 2 and eTable 12 in Supplement 2). Associations remained statistically significant in subset analyses by age and sex; there were weaker RRs in older adults (≥65 years of age) compared with younger adults (<65 years of age) (median difference in log HRs, −0.14 [IQI, −0.36 to 0.03], *P* < .001), but not in women compared with men (median difference in log HRs, −0.002 [IQI, −0.10 to 0.11], *P* = .53; eTable 13 in Supplement 2).

The differences in the adjusted HRs for eGFR based on creatinine and cystatin C between the older and younger age groups were smaller than those seen with eGFR based on creatinine alone (median difference in differences, −0.16 [IQI, −0.34 to −0.01], *P* < .001; eTable 13 in Supplement 2). The risk for all outcomes was increased in the CKD category of G3a (eGFR category of 45–59 mL/min/1.73 m² based on creatinine and cystatin C) even among people with a UACR less than 10 mg/g, and these risks remained statistically significant in the subset analyses by age and sex (eTable 14 in Supplement 2). Compared with the analyses using eGFR based on creatinine alone, the risk associations with eGFR based on creatinine and cystatin C were stronger and less U-shaped (median difference in log HRs, 0.10 [IQI, 0.02 to 0.21], *P* < .001; Figure 3).

Associations with alternative estimating equations for GFR appear in eTable 15 in Supplement 2. The alternative estimating equations were highly correlated with eGFR using the CKD-EPI 2021 equation in all cohorts (range of Pearson correlation coefficients, 0.98–1.00 for eGFR based on creatinine alone using the CKD-EPI 2021 and EKFC equations; range of Pearson correlation coefficients, 0.93–0.99 for eGFR based on creatinine and cystatin C using the CKD-EPI 2021 and EKFC equations; range of Pearson correlation coefficients, 0.99–1.00 for eGFR based on creatinine alone using the CKD-EPI 2021 and CKD-EPI 2009 NB equations; and range of Pearson correlation coefficients, 0.996–1.00 for eGFR based on creatinine and cystatin C using the CKD-EPI 2021 and CKD-EPI 2012 NB equations).

Prevalence of CKD and Incidence of Adverse Outcomes

Of the included individuals in the cohorts from the Optum Labs Data Warehouse, 63% were missing a measure of albuminuria (including dipstick measures). The prevalence of each category of eGFR based on creatinine alone was similar with and without the inclusion of those missing a measure of albuminuria. For example, the prevalence of eGFR less than 60 mL/min/1.73 m² (based on creatinine alone) was 9.6% when individuals missing a measure of albuminuria were included and was 10% when those missing a measure of albuminuria were excluded. Among those with measures of albuminuria, the prevalence of the UACR category of 30 to 299 mg/g (category A2) was 9.9%, 3.1% had the UACR category of 300 to 999 mg/g, and 1.2% had the UACR category of 1000 mg/g or greater (eTable 16 in Supplement 2).

The unadjusted incidence rate for each adverse outcome was higher with more severe categories of eGFR

Figure 1. Categorical Analysis of the Associations of Estimated Glomerular Filtration Rate (eGFR) and Albuminuria With Subsequent Adverse Outcomes in the Population Based on Creatinine Alone

Overall	Urine albumin to creatinine ratio, mg/g					Urine albumin to creatinine ratio, mg/g				
	<10	10-29	30-299	300-999	≥1000	<10	10-29	30-299	300-999	≥1000
eGFR, mL/min/1.73 m ² using creatinine alone	All-cause mortality: 82 cohorts 26 444 384 participants; 2 604 028 events					Myocardial infarction: 64 cohorts 22 838 356 participants; 451 063 events				
≥105	1.6	2.2	2.9	4.3	5.8	1.1	1.4	2.0	2.7	3.8
90-104	Reference	1.3	1.8	2.6	3.1	Reference	1.3	1.6	2.2	3.2
60-89	1.0	1.3	1.7	2.2	2.8	1.1	1.3	1.6	2.2	3.1
45-59	1.3	1.6	2.0	2.4	3.1	1.4	1.7	2.0	2.8	3.7
30-44	1.8	2.0	2.5	3.2	3.9	1.9	2.0	2.4	3.2	4.3
15-29	2.8	2.8	3.3	4.1	5.6	2.7	3.1	3.1	4.2	5.1
<15	4.6	5.0	5.3	6.0	7.0	4.6	5.6	4.8	6.0	6.0
eGFR, mL/min/1.73 m ² using creatinine alone	Cardiovascular mortality: 76 cohorts 26 022 346 participants; 776 441 events					Stroke: 68 cohorts 24 746 436 participants; 461 785 events				
≥105	1.4	2.0	3.0	4.1	5.4	1.2	1.6	2.2	3.1	4.3
90-104	Reference	1.3	1.9	2.7	3.6	Reference	1.3	1.6	2.4	3.1
60-89	1.0	1.4	1.7	2.4	3.2	1.1	1.3	1.7	2.2	3.0
45-59	1.4	1.7	2.2	2.8	3.8	1.4	1.6	1.9	2.3	2.9
30-44	2.0	2.3	2.8	3.7	4.6	1.6	1.7	2.0	2.4	3.0
15-29	3.2	3.1	3.5	5.0	6.5	1.8	2.1	2.1	2.7	3.0
<15	6.1	6.4	6.4	7.3	8.2	3.2	2.8	2.9	3.2	3.8
eGFR, mL/min/1.73 m ² using creatinine alone	Kidney failure with replacement therapy: 57 cohorts 25 466 956 participants; 158 846 events					Heart failure: 61 cohorts 24 603 016 participants; 1 132 443 events				
≥105	0.5	1.2	2.9	7.7	25	1.2	1.7	2.7	4.2	6.9
90-104	Reference	1.8	4.3	12	43	Reference	1.3	2.0	2.8	4.2
60-89	2.3	4.9	10	27	85	1.1	1.4	1.9	2.7	4.2
45-59	13	19	37	89	236	1.6	1.8	2.4	3.4	5.0
30-44	50	58	115	240	463	2.2	2.5	3.1	4.2	6.5
15-29	283	301	443	796	1253	3.6	3.5	4.1	5.8	8.1
<15	770	1040	1618	2297	2547	5.1	5.7	5.8	7.9	9.9
eGFR, mL/min/1.73 m ² using creatinine alone	Acute kidney injury: 49 cohorts 23 914 614 participants; 1 408 929 events					Atrial fibrillation: 50 cohorts 22 886 642 participants; 1 068 701 events				
≥105	1.0	1.6	2.4	3.7	5.5	1.1	1.3	1.7	2.4	3.5
90-104	Reference	1.4	2.1	3.2	5.0	Reference	1.2	1.5	1.9	2.3
60-89	1.6	2.2	3.1	4.3	6.7	1.0	1.2	1.4	1.7	2.2
45-59	3.5	4.0	5.1	6.9	9.0	1.2	1.3	1.5	1.8	2.4
30-44	5.6	5.9	6.8	8.6	11	1.4	1.5	1.7	2.0	2.4
15-29	8.3	8.0	8.5	9.9	10	1.9	1.8	2.0	2.6	3.0
<15	8.5	11	7.9	5.5	5.7	2.6	2.5	3.1	3.6	4.2
eGFR, mL/min/1.73 m ² using creatinine alone	Hospitalization: 49 cohorts 25 426 722 participants; 839 863 events					Peripheral artery disease: 54 cohorts 24 830 794 participants; 378 924 events				
≥105	1.4	1.7	2.1	2.1	2.3	0.9	1.4	1.9	2.8	5.0
90-104	Reference	1.1	1.3	1.5	1.7	Reference	1.3	1.9	2.8	4.3
60-89	1.0	1.1	1.3	1.5	1.8	1.0	1.3	1.8	2.5	3.8
45-59	1.3	1.3	1.5	1.7	2.1	1.5	1.7	2.1	2.9	4.2
30-44	1.5	1.5	1.6	1.9	2.3	2.0	1.9	2.5	3.6	5.0
15-29	1.8	1.8	1.9	2.4	2.8	3.3	3.3	3.8	5.7	8.1
<15	2.7	2.8	3.0	3.2	3.8	9.1	9.0	9.6	13	14

The numbers in the boxes reflect the adjusted hazard ratio vs the reference category. The adjustment variables appear in the legend for Figure 2. The sample sizes include individuals who are missing a measure of albuminuria. The percentile shaded the darkest green color corresponds to the proportion of cells in the grid without chronic kidney

disease (eg, 6 of 35 cells with eGFR ≥60 mL/min/1.73 m² and urine albumin to creatinine ratio <30 mg/g), and the percentile shaded the darkest red color corresponds to the proportion expected to be at the highest risk for adverse outcomes (eg, 11 of 35 cells with eGFR <15 mL/min/1.73 m² and urine albumin to creatinine ratio ≥1000 mg/g).

Table 2. Adjusted Hazard Ratios of Subsequent Adverse Outcomes for Individuals With Mild to Moderate Kidney Disease

	Estimated glomerular filtration rate (eGFR), adjusted hazard ratio (95% CI) ^a						
	eGFR based on creatinine alone				eGFR based on creatinine and cystatin C		
	eGFR of 90-104 mL/min/1.73 m ² and UACR <10 mg/g	eGFR of 45-59 mL/min/1.73 m ² and UACR <10 mg/g	eGFR of 45-59 mL/min/1.73 m ² and UACR of 10-29 mg/g	eGFR of 45-59 mL/min/1.73 m ² and missing UACR	eGFR of 90-104 mL/min/1.73 m ² and UACR <10 mg/g	eGFR of 45-59 mL/min/1.73 m ² and UACR <10 mg/g	eGFR of 45-59 mL/min/1.73 m ² and UACR of 10-29 mg/g
All-cause mortality	1 [Reference]	1.3 (1.2-1.4)	1.6 (1.5-1.7)	1.6 (1.5-1.7)	1 [Reference]	1.7 (1.5-1.8)	2.2 (2.1-2.3)
Cardiovascular mortality	1 [Reference]	1.4 (1.3-1.4)	1.7 (1.5-1.9)	1.6 (1.4-1.8)	1 [Reference]	1.9 (1.6-2.2)	2.7 (2.4-3.0)
Kidney failure with replacement therapy	1 [Reference]	12.7 (11.1-14.6)	19.0 (15.6-23.1)	17.7 (14.2-22.1)	1 [Reference]	5.8 (2.4-14.2)	12.5 (5.4-29.1)
Acute kidney injury	1 [Reference]	3.5 (3.3-3.7)	4.0 (3.7-4.3)	3.8 (3.5-4.2)	1 [Reference]	3.9 (3.5-4.4)	4.7 (4.2-5.2)
Hospitalization	1 [Reference]	1.3 (1.2-1.3)	1.3 (1.3-1.4)	1.2 (1.2-1.3)	1 [Reference]	1.3 (1.1-1.5)	1.4 (1.1-1.7)
Coronary heart disease	1 [Reference]	1.4 (1.3-1.5)	1.7 (1.6-1.8)	1.6 (1.4-1.8)	1 [Reference]	1.6 (1.3-2.0)	2.0 (1.7-2.3)
Stroke	1 [Reference]	1.4 (1.3-1.5)	1.6 (1.5-1.7)	1.5 (1.4-1.7)	1 [Reference]	1.6 (1.4-1.9)	1.8 (1.5-2.2)
Heart failure	1 [Reference]	1.6 (1.5-1.7)	1.8 (1.7-2.0)	1.9 (1.8-2.1)	1 [Reference]	1.5 (1.1-2.1)	2.2 (1.8-2.8)
Atrial fibrillation	1 [Reference]	1.2 (1.2-1.3)	1.3 (1.3-1.4)	1.4 (1.3-1.5)	1 [Reference]	1.3 (1.1-1.5)	1.6 (1.5-1.9)
Peripheral artery disease	1 [Reference]	1.5 (1.3-1.6)	1.8 (1.6-2.0)	1.9 (1.6-2.1)	1 [Reference]	2.5 (1.5-4.2)	3.7 (2.7-4.9)

Abbreviation: UACR, urine albumin to creatinine ratio.

^a The adjustment variables included age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body mass index, use of antihypertensive medications, and a history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease when relevant. All models appear in eAppendix 1 in

Supplement 1. The cohorts used in these analyses are the general population and electronic health record cohorts (the chronic kidney disease cohorts did not have sufficient individuals in the reference groups) and those missing a measure of albuminuria were included. All comparisons yielded $P < .001$. The number of cohorts appears in Figure 1 and Figure 2 and the cell-specific sample sizes and number of events appear in eTables 6 and 12 in Supplement 2.

and UACR. Hospitalizations were the most common adverse outcome. In the reference group (eGFR 90-104 mL/min/1.73 m² and UACR <10 mg/g), the rate of hospitalizations was 79 per 1000 person-years, the rate for all-cause mortality was 11 per 1000 person-years, the rate for acute kidney injury was 4.5 per 1000 person-years, the rate for atrial fibrillation was 4.0 per 1000 person-years, the rate for heart failure was 3.9 per 1000 person-years, the rate for cardiovascular mortality was 2.3 per 1000 person-years, the rate for stroke was 2.1 per 1000 person-years, the rate for myocardial infarction was 1.7 per 1000 person-years, the rate for peripheral artery disease was 0.6 per 1000 person-years, and the rate for kidney failure with replacement therapy was 0.1 per 1000 person-years (eTable 17 in Supplement 2).

Among people with a UACR less than 10 mg/g, an eGFR of 45 to 59 mL/min/1.73 m² based on creatinine alone was associated with significantly higher hospitalization rates compared with an eGFR of 90 to 104 mL/min/1.73 m² (adjusted HR, 1.3 [95% CI, 1.2-1.3]; 161 vs 79 events per 1000 person-years; excess absolute risk, 22 events per 1000 person-years [95% CI, 19-25 events per 1000 person-years]). For the most severe CKD categories (eGFR <15 mL/min/1.73 m² and UACR ≥1000 mg/g), the highest rates of adverse outcomes were for hospitalizations (562 per 1000 person-years), kidney failure with replacement therapy (325 per 1000 person-years), and mortality (148 per 1000 person-years). The adjusted excess mortality appears in eTable 18 in Supplement 2. The unadjusted incidence rates by age and sex appear in eTables 19-22 in Supplement 2.

Discussion

This individual-participant data meta-analysis of more than 27 million adults evaluated associations of eGFR and albuminuria with 10 adverse outcomes that included kidney outcomes, all-cause mortality, cardiovascular mortality, hospitalizations, and other cardiovascular events. There were strong graded associations with lower eGFR and adverse outcomes for the new, race-free 2021 CKD-EPI equation for eGFR based on creatinine alone⁷ and also when cystatin C was included as an additional filtration marker in eGFR (based on creatinine and cystatin C). The pattern of associations persisted irrespective of age, sex, diabetes, and cardiovascular disease and were stronger for eGFR based on creatinine and cystatin C compared with eGFR based on creatinine alone. This work supports recent recommendations to increase the use of cystatin C in clinical practice.^{17,18}

Prior meta-analyses of eGFR and albuminuria with adverse outcomes evaluated only 5 adverse outcomes in 1.2 million individuals within 21 cohorts from 14 countries.²⁻⁶ These reports used eGFR based on creatinine alone; the Modification of Diet in Renal Disease study equation, which includes race; and an unvalidated equation to impute UACR from the ratio of urine protein to creatinine. In the current study, eGFR was calculated using the race-free estimating equations for both eGFR based on creatinine alone and eGFR based on creatinine and cystatin C per 2021 recommendations from the

Figure 2. Categorical Analysis of the Associations of Estimated Glomerular Filtration Rate (eGFR) and Albuminuria With Subsequent Adverse Outcomes in the Population Based on Creatinine and Cystatin C

Overall	Urine albumin to creatinine ratio, mg/g				Urine albumin to creatinine ratio, mg/g			
	<10	10-29	30-299	≥300	<10	10-29	30-299	≥300
eGFR, mL/min/1.73 m ² using creatinine and cystatin C	All-cause mortality: 11 cohorts 692 802 participants; 97 006 events				Myocardial infarction: 10 cohorts 649 365 participants; 17 926 events			
≥105	1.0	1.3	1.6	2.5	0.9	1.2	1.4	2.8
90-104	Reference	1.3	1.5	2.0	Reference	1.2	1.4	1.8
60-89	1.2	1.5	1.9	2.5	1.2	1.4	1.5	1.9
45-59	1.7	2.2	2.5	3.3	1.6	1.9	2.3	3.3
30-44	2.3	2.6	3.4	4.4	2.1	2.6	3.1	3.3
<30	3.6	4.0	5.5	7.1	5.1	3.0	4.9	5.0
eGFR, mL/min/1.73 m ² using creatinine and cystatin C	Cardiovascular mortality: 11 cohorts 692 322 participants; 25 322 events				Stroke: 9 cohorts 662 605 participants; 16 909 events			
≥105	1.0	1.4	1.8	4.1	1.0	1.2	1.6	2.5
90-104	Reference	1.5	1.6	2.9	Reference	1.2	1.5	2.3
60-89	1.2	1.7	2.3	3.4	1.2	1.4	1.8	2.5
45-59	1.9	2.7	3.2	4.6	1.6	1.7	2.1	2.7
30-44	2.5	3.5	4.5	5.9	1.7	2.0	2.3	2.6
<30	5.8	5.0	6.1	8.7	1.9	2.3	2.8	4.4
eGFR, mL/min/1.73 m ² using creatinine and cystatin C	Kidney failure with replacement therapy: 5 cohorts 630 370 participants; 4306 events				Heart failure: 9 cohorts 641 298 participants; 27 406 events			
≥105	0.6	0.8	2.3	10	0.9	1.2	1.7	3.7
90-104	Reference	1.5	4.5	11	Reference	1.3	1.4	2.5
60-89	1.9	3.7	8.3	31	1.2	1.6	1.9	3.0
45-59	5.8	13	25	73	1.5	2.2	3.0	4.1
30-44	20	23	78	191	2.5	2.9	4.1	5.7
<30	111	261	343	580	5.3	4.8	6.5	7.7
eGFR, mL/min/1.73 m ² using creatinine and cystatin C	Acute kidney injury: 5 cohorts 630 370 participants; 24 062 events				Atrial fibrillation: 5 cohorts 607 102 participants; 37 278 events			
≥105	0.8	1.0	1.4	3.5	0.9	1.0	1.1	1.9
90-104	Reference	1.3	1.7	2.8	Reference	1.2	1.4	2.2
60-89	1.6	2.5	2.9	5.3	1.1	1.3	1.5	2.0
45-59	3.9	4.7	5.5	7.5	1.3	1.6	1.8	2.2
30-44	5.8	7.0	8.4	10	1.6	2.0	2.2	2.5
<30	11	12	12	21	2.0	2.0	2.7	4.4
eGFR, mL/min/1.73 m ² using creatinine and cystatin C	Hospitalization: 3 cohorts 630 489 participants; 464 894 events				Peripheral artery disease: 6 cohorts 642 624 participants; 3943 events			
≥105	1.0	1.1	1.1	1.6	0.9	1.9	1.8	2.9
90-104	Reference	1.1	1.3	1.4	Reference	1.5	2.0	3.2
60-89	1.1	1.2	1.3	1.6	1.3	1.8	2.1	3.9
45-59	1.3	1.4	1.5	1.7	2.5	3.7	3.3	4.0
30-44	1.5	1.5	1.6	2.1	4.0	3.7	4.5	6.9
<30	1.8	2.0	2.1	3.0	7.8	4.5	9.0	12


The numbers in the boxes reflect the adjusted hazard ratio compared with the reference category. The adjustment variables included age, sex, smoking status (current, former, never), systolic blood pressure, total cholesterol, high-density lipoprotein cholesterol, body mass index, use of antihypertensive medications, and a history of diabetes, coronary heart disease, stroke, heart failure, atrial fibrillation, peripheral artery disease, cancer, and chronic obstructive pulmonary disease when relevant. The cohorts used in these analyses are the general population and electronic health record cohorts (the chronic kidney disease [CKD] cohorts did not have sufficient individuals in the reference cells). The sample sizes include individuals who are missing a measure of albuminuria. The percentile shaded the darkest green color corresponds to the proportion of cells in the grid without CKD (eg, 6 of 24 cells), and the percentile shaded the darkest red color corresponds to the proportion expected to be at the highest risk for adverse outcomes (eg, 5 of 24 cells).

National Kidney Foundation and the American Society of Nephrology.^{17,18} The UACR was imputed from the ratio of urine protein to creatinine or the urine dipstick protein using a validated equation.^{12,19} The current study adds to the literature by providing strong evidence for the classification and risk stratification of CKD using the most up-to-date estimates of GFR, more categories of albuminuria, and additional cardiovascu-

lar outcomes. The use of 114 cohorts from across the world enhances the generalizability of the results.

The results underscore the importance of albuminuria in risk assessment. Even mildly elevated UACR (category A2; UACR of 30-299 mg/g) was statistically significantly associated with increased risk for all outcomes. The adjusted excess risk of mortality associated with a UACR of 300 to 999 mg/g

Figure 3. Hazard Ratios for Adverse Outcomes Using a Continuous Model of Estimated Glomerular Filtration Rate (eGFR)



The diamond indicates the reference point at eGFR of 90 mL/min/1.73 m². The dots indicate that the 95% CI for the hazard ratio from this spline model does not include 1.0.

and an eGFR of 90 to 104 mL/min/1.73 m² was comparable with that of stage 1 colon cancer (17 deaths per 1000 person-years and a 5-year survival rate of 91%).²⁰ Similar to previous observations,²¹ the current study demonstrates low rates of albuminuria measurement in electronic health records.

Some guidelines recommend cystatin C testing in patients with CKD, and others discourage measurement of cystatin C.^{2,22} The current study provides evidence for the potential utility of eGFR based on creatinine and cystatin C. With eGFR based on creatinine alone, there was a U-shaped association with the study outcomes, indicating a higher risk with both lower eGFR (<60 mL/min/1.73 m²) and higher eGFR (>105 mL/min/1.73 m²). This finding may indicate imprecision and systematic overestimation of GFR among people who

progress to adverse events (thus contributing to the U-shaped curve). There was a more linear risk relationship for eGFR when based on both creatinine and cystatin C.

Both creatinine and cystatin C values are affected by clinical characteristics independent of GFR,²³ and the most widely recognized non-GFR determinant for creatinine is muscle mass.²⁴ Persons with low muscle mass, on average, have higher eGFR based on creatinine alone than eGFR based on creatinine and cystatin C.²⁵ Differences in RRs between eGFR based on creatinine alone and eGFR based on creatinine and cystatin C were observed among older adults (≥65 years of age), suggesting that when clinically available, additional use of cystatin C could better identify high-risk individuals, particularly among older populations.

This study has several strengths. First, the sample size was large and included adults from multiple countries. Second, the most recent eGFR equations were evaluated. Third, the results suggested that deviations in risk associations across type, geographic location, and cohort characteristics were unlikely. Fourth, the subgroup analyses demonstrated the higher risk for adverse outcomes associated with lower eGFR and higher UACR across categories of age, sex, presence of diabetes, and history of cardiovascular disease.

Limitations

This study has several limitations. First, other estimating equations of GFR were not comprehensively tested.^{14,16} Second, the included cohorts used different study designs and protocols for outcome ascertainment. The outcomes were often based on *International Classification of Diseases* codes, which have variable sensitivity and specificity for each outcome measure.

Third, cystatin C was available in only a subset of cohorts. Fourth, the data used in the analyses were observational and causal inferences should not be made.²⁶ Fifth, although the findings support the use of eGFR based on creatinine and cystatin C in the detection and staging of CKD, cystatin C is not widely available and may be expensive to routinely measure. Sixth, some variables such as baseline heart failure were missing from several cohorts and may have confounded the relationship between eGFR and the outcomes, particularly for acute kidney injury.

Conclusions

In this retrospective analysis of 114 cohorts, lower eGFR based on creatinine alone, lower eGFR based on creatinine and cystatin C, and more severe UACR were each associated with increased rates of 10 adverse outcomes, including adverse kidney outcomes, cardiovascular diseases, and hospitalizations.

ARTICLE INFORMATION

Accepted for Publication: August 15, 2023.

Writing Group for the CKD Prognosis

Consortium: Morgan E. Grams, MD, PhD; Josef Coresh, MD, PhD; Kunihiro Matsushita, MD, PhD; Shoshana H. Ballew, PhD; Yingying Sang, MS; Aditya Surapaneni, PhD; Natalia Alencar de Pinho, PhD; Amanda Anderson, PhD; Lawrence J. Appel, MD; Johan Ärnlöv, MD, PhD; Fereidoun Azizi, MD; Nisha Bansal, MD; Samira Bell, MD; Henk J. G. Bilo, MD, PhD; Nigel J. Brunskill, MBChB, PhD; Juan J. Carrero, PhD; Steve Chadban, MD, PhD; John Chalmers, MD, PhD; Jing Chen, MSc, MD; Elizabeth Cierns, MPH, PhD; Massimo Cirillo, MD; Natalie Ebert, MPH, MD; Marie Evans, MD, PhD; Alejandro Ferreira, MD; Edouard L. Fu, PhD; Masafumi Fukagawa, MD, PhD; Jamie A. Green, MD; Orlando M. Gutierrez, MD; William G. Herrington, MD; Shih-Jen Hwang, PhD; Lesley A. Inker, MD; Kunitoshi Iseki, MD; Tazeen Jafar, MPH, MD; Simerjot K. Jassal, MD; Vivekanand Jha, MD, DM; Aya Kadota, MD, PhD; Ronit Katz, DPhil; Anna Köttgen, MD, MPH; Tsuneo Konta, MD; Florian Kronenberg, MD; Brian J. Lee, MD; Jennifer Lees, MBChB, PhD; Adeera Levin, MD; Helen C. Looker, MBBS; Rupert Major, MD, PhD; Cheli Melzer Cohen, MSc; Makiko Mieno, PhD; Mariko Miyazaki, MD, PhD; Olivier Moranne, MD, PhD; Isao Muraki, MD, PhD; David Naimark, MD, MSc; Dorothea Nitsch, MD; Wonsuk Oh, PhD; Michelle Pena, MPH, PhD; Tanjala S. Purnell, MPH, PhD; Charumathi Sabanayagam, MPH, MD, PhD; Michihiro Satoh, PhD; Simon Sawhney, MD, PhD; Elke Schaeffner, MSc, MD; Ben Schöttker, PhD; Jenny I. Shen, MD; Michael G. Shlipak, MPH, MD; Smeeta Sinha, MBChB, PhD; Benedicte Stengel, MD, PhD; Keiichi Sumida, MPH, MD, PhD; Marcello Tonelli, MD; Jose M. Valdivielso, PhD; Arjan D. van Zuiden, MD; Frank L. J. Visseren, MD, PhD; Angela Yee-Moon Wang, MD, PhD; Chi-Pang Wen, MD, DrPH; David C. Wheeler, MD; Hiroshi Yatsuya, MD, PhD; Kunihiro Yamagata, MD, PhD; Jae won Yang, MD; Ann Young, MD, PhD; Haitao Zhang, PhD; Luxia Zhang, MPH, MD; Andrew S. Levey, MD; Ron T. Gansevoort, MD, PhD.

Affiliations of Writing Group for the CKD

Prognosis Consortium: Division of Precision Medicine, Department of Medicine, Grossman

School of Medicine, New York University, New York, New York (Grams, Surapaneni); Department of Epidemiology and Welch Center for Prevention, Epidemiology, and Clinical Research, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland (Grams, Coresh, Matsushita, Ballew, Sang, Appel, Purnell); Centre for Research in Epidemiology and Population Health, Paris-Saclay University, Inserm U1018, Versailles Saint-Quentin University, Clinical Epidemiology Team, Villejuif, France (Alencar de Pinho, Stengel); School of Public Health and Tropical Medicine, Tulane University, New Orleans, Louisiana (Anderson); School of Health and Social Studies, Dalarna University, Falun, Sweden (Ärnlöv); Department of Neurobiology, Care Sciences, and Society, Family Medicine and Primary Care Unit, Karolinska Institutet, Huddinge, Sweden (Ärnlöv); Endocrine Research Center, Research Institute for Endocrine Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran (Azizi); Division of Nephrology, University of Washington, Seattle (Bansal); Division of Population Health and Genomics, School of Medicine, University of Dundee, Dundee, Scotland (Bell); Diabetes Centre and Department of Internal Medicine, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (Bilo); Department of Cardiovascular Sciences, University of Leicester, and John Walls Renal Unit, Leicester General Hospital, University Hospitals of Leicester NHS Trust, Leicester, England (Brunskill, Major); Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, and Department of Clinical Science, Danderyd Hospital, Stockholm, Sweden (Carrero); Department of Renal Medicine, Royal Prince Alfred Hospital, Sydney, Australia (Chadban); George Institute for Global Health, University of New South Wales, Sydney, Australia (Chalmers); School of Public Health, Imperial College, London, England (Chalmers); Prasanna School of Public Health, Manipal Academy of Higher Education, Manipal, India (Chalmers); Department of Medicine, School of Medicine, Tulane University, New Orleans, Louisiana (Chen); AMGA (American Medical Group Association), Alexandria, Virginia (Cierns); Department Scuola Medica Salernitana, University of Salerno, Fisciano, Italy (Cirillo); Institute of Public Health, Charité Universitätsmedizin Berlin, Berlin,

Germany (Ebert, Schaeffner); Department of Renal Medicine, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden (Evans); Departamento de Nefrología, Facultad de Medicina, Universidad de la República, Montevideo, Uruguay (Ferreiro); Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts (Fu); Division of Nephrology, Endocrinology, and Metabolism, School of Medicine, Tokai University, Isehara, Japan (Fukagawa); Department of Nephrology, Geisinger Commonwealth School of Medicine, Danville, Pennsylvania (Green); Center for Kidney Health Research, Geisinger, Danville, Pennsylvania (Green); Division of Nephrology, University of Alabama at Birmingham (Gutierrez); Medical Research Council Population Health Research Unit, University of Oxford, Oxford, England (Herrington); Clinical Trial Service Unit and Epidemiological Studies Unit, University of Oxford, Oxford, England (Herrington); Framingham Heart Study, Framingham, Massachusetts (Hwang); Population Sciences Branch, Division of Intramural Research, National Heart, Lung, and Blood Institute, Bethesda, Maryland (Hwang); Division of Nephrology, Tufts Medical Center, Boston, Massachusetts (Inker, Levey); Okinawa Heart and Renal Association, Okinawa, Japan (Iseki); Programme in Health Services and Systems Research, Duke-NUS Medical School, Singapore (Jafar); Duke Global Health Institute, Duke University, Durham, North Carolina (Jafar); University of California-San Diego, La Jolla (Jassal); San Diego VA Health Care System, San Diego, California (Jassal); George Institute for Global Health India, New Delhi, India (Jha); George Institute for Global Health, School of Public Health, Imperial College, London, England (Jha); Department of Public Health, NCD Epidemiology Research Center, Shiga University of Medical Science, Otsu, Japan (Kadota); Department of Obstetrics and Gynecology, University of Washington, Seattle (Katz); Institute of Genetic Epidemiology, Faculty of Medicine and Medical Center, University of Freiburg, Freiburg, Germany (Köttgen); Department of Public Health and Hygiene, Yamagata University Faculty of Medicine, Yamagata, Japan (Konta); Institute of Genetic

Epidemiology, Medical University of Innsbruck, Innsbruck, Austria (Kronenberg); Kaiser Permanente, Hawaii Region, and Moanalua Medical Center, Honolulu, Hawai'i (Lee); School of Cardiovascular and Metabolic Health, University of Glasgow, Glasgow, Scotland (Lees); Glasgow Renal and Transplant Unit, Queen Elizabeth University Hospital, Glasgow, Scotland (Lees); Division of Nephrology, University of British Columbia, Vancouver, Canada (Levin); Chronic Kidney Disease Section, National Institute of Diabetes and Digestive and Kidney Diseases, Phoenix, Arizona (Looker); Maccabi Institute for Research and Innovation, Maccabi Healthcare Services, Tel-Aviv, Israel (Melzer Cohen); Department of Medical Informatics, Center for Information, Jichi Medical University, Tochigi, Japan (Mieno); Department of Nephrology, Endocrinology, and Vascular Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan (Miyazaki); Service de Néphrologie Dialyse Aphasée, Nîmes Hôpital Universitaire, Nîmes, France (Moranne); IDESP, UMR-INSEERM, Université de Montpellier, Montpellier, France (Moranne); Public Health, Osaka University Graduate School of Medicine, Suita, Japan (Muraki); Department of Medicine and Institute of Health Policy, Management, and Evaluation, University of Toronto, Toronto, Ontario, Canada (Naimark); London School of Hygiene and Tropical Medicine, London, England (Nitsch); Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, New York (Oh); Department of Clinical Pharmacy and Pharmacology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands (Pena); Division of Transplantation, Department of Surgery, School of Medicine, Johns Hopkins University, Baltimore, Maryland (Purnell); Center for Health Equity, Johns Hopkins University, Baltimore, Maryland (Purnell); Singapore Eye Research Institute, Singapore National Eye Centre, Singapore (Sabanayagam); Ophthalmology and Visual Sciences Academic Clinical Programme, Duke-NUS Medical School, Singapore (Sabanayagam); Division of Public Health, Hygiene, and Epidemiology, Tohoku Medical and Pharmaceutical University, Sendai, Japan (Satoh); Aberdeen Centre for Health Data Science, School of Medicine, Medical Sciences, and Nutrition, University of Aberdeen, Aberdeen, Scotland (Sawhney); NHS Grampian, Aberdeen, Scotland (Sawhney); Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Heidelberg, Germany (Schöttker); Department of Medicine, David Geffen School of Medicine, University of California, Los Angeles (Shen); Lundquist Institute, Harbor-UCLA Medical Center, Torrance, California (Shen); Kidney Health Research Collaborative, Department of Medicine, University of California, San Francisco (Shlipak); General Internal Medicine Division, Medical Service, San Francisco Veterans Affairs Health Care System, San Francisco, California (Shlipak); Salford Royal Hospital, Northern Care Alliance NHS Foundation Trust, Salford, England (Sinha); Division of Nephrology, Department of Medicine, University of Tennessee Health Science Center, Memphis (Sumida); Department of Medicine, University of Calgary, Calgary, Alberta, Canada (Tonelli); Vascular and Renal Translational Research Group, Biomedical Research Institute of Lleida, IRBLleida and University of Lleida, Lleida, Spain (Valdivielso); Department of Nephrology and Hypertension,

University Medical Center Utrecht, Utrecht, the Netherlands (van Zuijlen); Department of Vascular Medicine, University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands (Visseren); Department of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China (Wang); Institute of Population Health Science, National Health Research Institutes, Zhunan, Taiwan/China Medical University Hospital, Taichung, Taiwan (Wen); Department of Renal Medicine, University College London, London, England (Wheeler); Department of Public Health and Health Systems, Nagoya University Graduate School of Medicine, Nagoya, Japan (Yatsuya); Department of Nephrology, University of Tsukuba, Tsukuba, Japan (Yamagata); Department of Internal Medicine, Wonju College of Medicine, Yonsei University, Wonju, South Korea (Yang); Division of Nephrology, Unity Health Toronto, University of Toronto, Toronto, Ontario, Canada (Young); ICES Western, London, Ontario, Canada (Young); National Clinical Research Center of Kidney Diseases, Jinling Hospital, Medical School of Nanjing University, Nanjing, China (H. Zhang); Peking University First Hospital, Beijing, China (L. Zhang); Department of Nephrology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands (Gansevoort).

Author Contributions: Dr Grams had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

Concept and design: Grams, Coresh, Matsushita, Carrero, Chadban, Fukagawa, Iseki, Jafar, Levin, Melzer Cohen, Nitsch, Shlipak, Wheeler, Levey, Gansevoort.

Acquisition, analysis, or interpretation of data: All authors.

Drafting of the manuscript: Grams, Ballew, Bansal, Iseki, Miyazaki, Shlipak, van Zuijlen.

Critical review of the manuscript for important intellectual content: All authors.

Statistical analysis: Sang, Surapaneni, Bell, Carrero, Hwang, Kadota, Lee, Mieno, Sawhney, van Zuijlen.

Obtained funding: Grams, Coresh, Ballew, Anderson, Appel, Chen, Major, Tonelli, Valdivielso, Levey.

Administrative, technical, or material support: Grams, Coresh, Ballew, Alencar de Pinho, Anderson, Appel, Azizi, Bansal, Brunskill, Chadban, Ciemins, Ferreira, Fu, Fukagawa, Green, Iseki, Jafar, Jha, Köttgen, Konta, Major, Melzer Cohen, Moranne, Nitsch, Purnell, Sabanayagam, Satoh, Sawhney, Shen, Valdivielso, Wang, Wen, Wheeler, Yang, H. Zhang.

Supervision: Grams, Coresh, Anderson, Appel, Carrero, Kadota, Levin, Major, Shlipak, Visseren, Yamagata, Gansevoort.

Conflict of Interest Disclosures: Dr Grams reported receiving nonfinancial support from KDIGO (Kidney Disease: Improving Global Outcomes) and the Korean Society of Nephrology and receiving personal fees from the Nephrology Self-Assessment Program. Dr Coresh reported receiving personal fees from Healthy.io. Dr Matsushita reported receiving personal fees from Kowa, Kyowa Kirin, Akebia, and AMGA. Dr Alencar de Pinho reported receiving grants from Fresenius Medical Care, GSK (formerly GlaxoSmithKline), Vifor France, Boehringer Ingelheim, and AstraZeneca. Dr Årnlöv reported receiving personal fees from AstraZeneca, Astellas, Novartis, and Boehringer Ingelheim. Dr Bell

reported receiving personal fees from GSK, AstraZeneca, and Bayer. Dr Brunskill reported receiving grants from Kidney Research UK. Dr Carrero reported receiving nonfinancial support from KDIGO. Dr Chalmers reported receiving grants from the National Health and Medical Research Council of Australia. Dr Ebert reported receiving personal fees from Bayer Leverkusen. Dr Evans reported receiving grants and personal fees from Astellas; receiving personal fees from AstraZeneca, Vifor, Fresenius Medical Care, and Baxter; and serving on a steering committee for the Swedish Renal Registry. Dr Fu reported receiving grants from the Dutch Scientific Organization. Dr Fukagawa reported receiving grants from Kyowa-Kirin and receiving personal fees from Bayer Yakuhin. Dr Gutierrez reported receiving personal fees from Amgen, Tarsus Cardio Inc, and Klick Health. Dr Herrington reported receiving grants from the UK Medical Research Council, Boehringer Ingelheim, and Eli Lilly. Dr Jha reported receiving personal fees from GSK, Boehringer Ingelheim, Travere, Vera, Zydus Cadilla, Bayer, AstraZeneca, Baxter Healthcare, Visterra, and George Clinical. Dr Konta reported receiving personal fees from Tanabe-Mitsubishi, AstraZeneca, Daiichi-Sankyo, Boehringer Ingelheim, Sanwakagaku, Chugai, Pfizer, Mochida, Bayer, Kowa, Novartis, Kyowa-Kirin, Astellas, and Ono and receiving grants from Daiichi-Sankyo, Mochida, Tanabe-Mitsubishi, Chugai, and Novartis. Dr Lees reported receiving personal fees from AstraZeneca. Dr Major reported receiving grants from Kidney Research UK and receiving personal fees from AstraZeneca UK. Dr Miyazaki reported receiving grants from Astellas, Kyowa-Kirin, Torii Pharmaceutical, and Chugai Pharmaceutical. Dr Nitsch reported serving on a steering committee for GSK; receiving grants from the Medical Research Council, the National Institute for Health and Care Research, and the Health Foundation; and being the UK Kidney Association director of informatics research. Dr Sawhney reported receiving grants from the Academy of Medical Sciences. Dr Schaeffner reported receiving grants from Bayer and a stipend from the National Kidney Foundation for editorial work for the *American Journal of Kidney Diseases*. Dr Shen reported receiving personal fees from Healthmap Solutions, Outset Medical, and Spectral Medical. Dr Shlipak reported receiving grants from Bayer Pharmaceuticals and receiving personal fees from Cricket Health, Intercept Pharmaceuticals, Boehringer Ingelheim, AstraZeneca, and Bayer Pharmaceuticals. Dr Sinha reported receiving personal fees from AstraZeneca, Amgen, Bayer, Boehringer Ingelheim, CSL Vifor, GSK, Johnson & Johnson, Novartis, and Sanofi-Genzyme and receiving grants from AstraZeneca, CSL Vifor, GSK, Sanofi-Genzyme, and Johnson & Johnson. Dr Stengel reported receiving grants from GSK, Fresenius Medical Care, Boehringer Ingelheim, and Vifor Fresenius. Dr Wheeler reported receiving personal fees from Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, Eledon, Galderma, GSK, Gilead, Janssen, Merck Sharp and Dohme, ProKidney, Tricida, Vifor, and Zydus. Dr Levey reported receiving personal fees from AstraZeneca. No other disclosures were reported.

Funding/Support: The CKD Prognosis Consortium data coordinating center is funded in part by program grant R01DK100446 from the National Institute of Diabetes and Digestive and Kidney Diseases and funding from the US National Kidney

Foundation. A variety of sources have supported enrollment and data collection including laboratory measurements and follow-up in the collaborating cohorts of the CKD Prognosis Consortium. These funding sources include government agencies such as national institutes of health and medical research councils as well as foundations and industry sponsors listed in eAppendix 3 in [Supplement 1](#).

Role of the Funder/Sponsor: The funders/sponsors had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Group Information: The members of the CKD Prognosis Consortium are listed in [Supplement 3](#).

Disclaimer: Some of the data were supplied by the US Renal Data System and some of the authors work for the US government (at institutions including the National Heart, Lung, and Blood Institute, the National Institute of Diabetes and Digestive and Kidney Diseases, and others). The interpretation and reporting of these data are the responsibility of the authors and in no way should be seen as an official policy or interpretation of the US government.

Data Sharing Statement: See [Supplement 4](#).

REFERENCES

- GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet*. 2020;395(10225):709-733. doi:10.1016/S0140-6736(20)30045-3
- Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. *Kidney Int Suppl*. 2013;3(1):1-150.
- Levey AS, de Jong PE, Coresh J, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO controversies conference report. *Kidney Int*. 2011;80(1):17-28. doi:10.1038/ki.2010.483
- Astor BC, Matsushita K, Gansevoort RT, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease: a collaborative meta-analysis of kidney disease population cohorts. *Kidney Int*. 2011;79(12):1331-1340. doi:10.1038/ki.2010.550
- Gansevoort RT, Matsushita K, van der Velde M, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated GFR and higher albuminuria are associated with adverse kidney outcomes: a collaborative meta-analysis of general and high-risk population cohorts. *Kidney Int*. 2011; 80(1):93-104. doi:10.1038/ki.2010.531
- van der Velde M, Matsushita K, Coresh J, et al; Chronic Kidney Disease Prognosis Consortium. Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality: a collaborative meta-analysis of high-risk population cohorts. *Kidney Int*. 2011;79(12):1341-1352. doi:10.1038/ki.2010.536
- Inker LA, Eneanya ND, Coresh J, et al; Chronic Kidney Disease Epidemiology Collaboration. New creatinine- and cystatin C-based equations to estimate GFR without race. *N Engl J Med*. 2021;385(19):1737-1749. doi:10.1056/NEJMoa2102953
- OptumLabs. *OptumLabs and OptumLabs Data Warehouse: Descriptions and Citation*. OptumLabs; 2020.
- Coresh J, Astor BC, McQuillan G, et al. Calibration and random variation of the serum creatinine assay as critical elements of using equations to estimate glomerular filtration rate. *Am J Kidney Dis*. 2002;39(5):920-929. doi:10.1053/ajkd.2002.32765
- Grubb A, Blirup-Jensen S, Lindström V, Schmidt C, Althaus H, Zegers I; IFCC Working Group on Standardisation of Cystatin C (WG-SCC). First certified reference material for cystatin C in human serum ERM-DA471/IFCC. *Clin Chem Lab Med*. 2010; 48(11):1619-1621. doi:10.1515/CCLM.2010.318
- NIST. Development of reference measurement procedures and reference materials for creatinine. Published March 29, 2009; updated June 2, 2021. Accessed March 6, 2023. <https://www.nist.gov/programs-projects/development-reference-measurement-procedures-and-reference-materials-creatinine>
- Sumida K, Nadkarni GN, Grams ME, et al; Chronic Kidney Disease Prognosis Consortium. Conversion of urine protein-creatinine ratio or urine dipstick protein to urine albumin-creatinine ratio for use in chronic kidney disease screening and prognosis: an individual participant-based meta-analysis. *Ann Intern Med*. 2020;173(6):426-435. doi:10.7326/M20-0529
- US Renal Data System. *2021 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States*. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2021.
- Levey AS, Stevens LA, Schmid CH, et al; CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. *Ann Intern Med*. 2009; 150(9):604-612. doi:10.7326/0003-4819-150-9-200905050-00006
- Inker LA, Schmid CH, Tighiouart H, et al; CKD-EPI Investigators. Estimating glomerular filtration rate from serum creatinine and cystatin C. *N Engl J Med*. 2012;367(1):20-29. doi:10.1056/NEJMoa1114248
- Pottel H, Björk J, Rule AD, et al. Cystatin C-based equation to estimate GFR without the inclusion of race and sex. *N Engl J Med*. 2023;388(4):333-343. doi:10.1056/NEJMoa2203769
- Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. *Am J Kidney Dis*. 2022;79(2):268-288.e1. doi:10.1053/j.ajkd.2021.08.003
- Delgado C, Baweja M, Crews DC, et al. A unifying approach for GFR estimation: recommendations of the NKF-ASN task force on reassessing the inclusion of race in diagnosing kidney disease. *J Am Soc Nephrol*. 2021;32(12): 2994-3015. doi:10.1681/ASN.2021070988
- Résimont G, Vranken L, Pottel H, et al. Estimating urine albumin to creatinine ratio from protein to creatinine ratio using same day measurement: validation of equations. *Clin Chem Lab Med*. 2022;60(7):1064-1072. doi:10.1515/cclm-2022-0049
- American Cancer Society medical and editorial content team. Survival rates for colorectal cancer. Accessed June 9, 2023. <https://www.cancer.org/cancer/types/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html>
- Shin JJ, Chang AR, Grams ME, et al; CKD Prognosis Consortium. Albuminuria testing in hypertension and diabetes: an individual-participant data meta-analysis in a global consortium. *Hypertension*. 2021;78(4):1042-1052. doi:10.1161/HYPERTENSIONAHA.121.17323
- National Institute of Health and Care Excellence. *Chronic Kidney Disease: Assessment and Management—National Institute for Health and Care Excellence Guidelines*. National Institute for Health and Care Excellence; 2021.
- Porrini E, Ruggerenti P, Luis-Lima S, et al. Estimated GFR: time for a critical appraisal. *Nat Rev Nephrol*. 2019;15(3):177-190. doi:10.1038/s41581-018-0080-9
- Nankivell BJ, Nankivell LFJ, Elder GJ, Gruenewald SM. How unmeasured muscle mass affects estimated GFR and diagnostic inaccuracy. *EClinicalMedicine*. 2020;29-30:100662. doi:10.1016/j.eclinm.2020.100662
- Ballew SH, Chen Y, Daya NR, et al. Frailty, kidney function, and polypharmacy: the Atherosclerosis Risk in Communities (ARIC) Study. *Am J Kidney Dis*. 2017;69(2):228-236. doi:10.1053/j.ajkd.2016.08.034
- Levey AS, Grams ME, Inker LA. Uses of GFR and albuminuria level in acute and chronic kidney disease. *N Engl J Med*. 2022;386(22):2120-2128. doi:10.1056/NEJMra2201153